BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 14529538)

  • 1. New insights into the molecular mechanisms of action of bisphosphonates.
    Rogers MJ
    Curr Pharm Des; 2003; 9(32):2643-58. PubMed ID: 14529538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular and molecular mechanisms of action of bisphosphonates.
    Rogers MJ; Gordon S; Benford HL; Coxon FP; Luckman SP; Monkkonen J; Frith JC
    Cancer; 2000 Jun; 88(12 Suppl):2961-78. PubMed ID: 10898340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates: from the laboratory to the clinic and back again.
    Russell RG; Rogers MJ
    Bone; 1999 Jul; 25(1):97-106. PubMed ID: 10423031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.
    Coxon FP; Helfrich MH; Van't Hof R; Sebti S; Ralston SH; Hamilton A; Rogers MJ
    J Bone Miner Res; 2000 Aug; 15(8):1467-76. PubMed ID: 10934645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical and molecular mechanisms of action of bisphosphonates.
    Rogers MJ; Crockett JC; Coxon FP; Mönkkönen J
    Bone; 2011 Jul; 49(1):34-41. PubMed ID: 21111853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonates: the first 40 years.
    Russell RG
    Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro.
    Benford HL; McGowan NW; Helfrich MH; Nuttall ME; Rogers MJ
    Bone; 2001 May; 28(5):465-73. PubMed ID: 11344045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages.
    Roelofs AJ; Thompson K; Ebetino FH; Rogers MJ; Coxon FP
    Curr Pharm Des; 2010; 16(27):2950-60. PubMed ID: 20722616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton.
    Rogers MJ; Mönkkönen J; Munoz MA
    Bone; 2020 Oct; 139():115493. PubMed ID: 32569873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.
    Luckman SP; Hughes DE; Coxon FP; Graham R; Russell G; Rogers MJ
    J Bone Miner Res; 1998 Apr; 13(4):581-9. PubMed ID: 9556058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship between the chemistry and biological activity of the bisphosphonates.
    Ebetino FH; Hogan AM; Sun S; Tsoumpra MK; Duan X; Triffitt JT; Kwaasi AA; Dunford JE; Barnett BL; Oppermann U; Lundy MW; Boyde A; Kashemirov BA; McKenna CE; Russell RG
    Bone; 2011 Jul; 49(1):20-33. PubMed ID: 21497677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonates: mode of action and pharmacology.
    Russell RG
    Pediatrics; 2007 Mar; 119 Suppl 2():S150-62. PubMed ID: 17332236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates.
    van beek E; Löwik C; van der Pluijm G; Papapoulos S
    J Bone Miner Res; 1999 May; 14(5):722-9. PubMed ID: 10320520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase.
    David P; Nguyen H; Barbier A; Baron R
    J Bone Miner Res; 1996 Oct; 11(10):1498-507. PubMed ID: 8889850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors.
    Van Beek ER; Löwik CW; Papapoulos SE
    Bone; 2002 Jan; 30(1):64-70. PubMed ID: 11792566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular mechanisms of action of bisphosphonates: current status.
    Roelofs AJ; Thompson K; Gordon S; Rogers MJ
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6222s-6230s. PubMed ID: 17062705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase.
    Bergstrom JD; Bostedor RG; Masarachia PJ; Reszka AA; Rodan G
    Arch Biochem Biophys; 2000 Jan; 373(1):231-41. PubMed ID: 10620343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
    Dunford JE; Thompson K; Coxon FP; Luckman SP; Hahn FM; Poulter CD; Ebetino FH; Rogers MJ
    J Pharmacol Exp Ther; 2001 Feb; 296(2):235-42. PubMed ID: 11160603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonates: from bench to bedside.
    Russell RG
    Ann N Y Acad Sci; 2006 Apr; 1068():367-401. PubMed ID: 16831938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Bisphosphonates: the molecular targets and mechanisms of action].
    Wada S; Kamiya S; Ono K
    Clin Calcium; 2005 May; 15(5):819-24. PubMed ID: 15876745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.